id3814.html
In development: Guidance, quality standards and advice
Tue, 11 Feb 2025 03:37:00 GMT
Pembrolizumab with olaparib for treating hormone-relapsed metastatic prostate cancer after abiraterone or enzalutamide and chemotherapy [ID3814] Technology appraisal guidance TBC Daratumumab with ...